Xyzagen Expands Team with Strategic Hires, Enhancing Quantitative Medicine and Genomics Capabilities
Pittsboro, NC – March 30, 2024 – Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), announced the successful expansion of its team with several key strategic hires in modeling and simulation and genomics. This move significantly enhanced the company’s capabilities in Quantitative Medicine and genomics, positioning Xyzagen for continued growth and leadership in pharmacokinetics within the rapidly evolving life sciences landscape.
The new hires, Matthew Rich, PhD, in quantitative medicine, population PK modeling, and Ashley Schultz, PhD in behavioral research and genomics, whose combined expertise will further strengthen Xyzagen’s ability to support client’s at an early drug discovery stage. With the additional focus on genomics and population PK solutions, Xyzagen is well-equipped to support early discovery research and late stage population PK analyses for NDA submissions. This growth also allows us to expand upon our model informed drug development platform to gain early insight into a client’s therapeutic’s pharmacokinetic profile.
“We are excited to welcome these talented professionals to our team,” said Christopher Crean, CEO and Founder of Xyzagen. “Their expertise in quantitative medicine and genomics will play a critical role in our mission to be a cost effective early discovery CRO for innovative clients.
About Xyzagen, Inc.
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine. Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. Xyzagen’s a boutique organization which allows small clients to work directly and strategically with experts during their drug development programs.
Media Contact:
Christopher Crean
Founder & CEO, Xyzagen, Inc.
Phone: (919) 762-2072
Email: [email protected]
